New fronts in the adjuvant treatment of GIST
- 722 Downloads
To review the prognostic factors and stratification systems used to determine the need for adjuvant therapy in the treatment of gastrointestinal stromal tumors (GIST), and to review recent clinical advances in investigation of the efficacy and safety of adjuvant imatinib mesylate treatment.
Recent data from clinical trials of various durations of adjuvant imatinib in GIST are reviewed, with emphasis on key results from the Phase III American College of Surgeons Oncology Group (ACOSOG) Z9001 trial and the Scandinavian Sarcoma Group XVIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) trial.
Complete surgical resection remains the standard of treatment for localized GISTs; however, disease recurrence occurs in up to 50 % of patients who undergo complete resection. The ACOSOG Z9001 trial established that 1 year of adjuvant imatinib reduces the risk of recurrence in patients with resected GIST. The SSGXVIII/AIO trial further demonstrated that 3-year adjuvant imatinib improves both recurrence-free survival and overall survival compared with 1-year therapy in patients at high risk of recurrence after surgery. Considering risk factors associated with tumor recurrence is essential for identifying the patients who are most likely to benefit from adjuvant imatinib.
Although the optimal duration of adjuvant therapy remains to be determined, results from these pivotal trials provide firm evidence that adjuvant imatinib improves recurrence-free survival and improved overall survival of patients in the SSGXVIII/AIO trial. Ongoing studies may shed further light on the benefits and harms of adjuvant therapy, as well as the most appropriate patient candidates for adjuvant imatinib treatment.
KeywordsGastrointestinal stromal tumor Imatinib Tyrosine kinase inhibitor KIT Metastatic Adjuvant
Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Jared Wels, PhD, for his medical editorial assistance with this manuscript.
- 3.National Comprehensive Cancer Center (2012) NCCN clinical practice guidelines in oncology: soft tissue sarcoma V2.2012. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 22 Aug 2012
- 16.Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRefGoogle Scholar
- 25.Rossi S, Miceli R, Messerini L et al (2011) Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 35:1646–1656PubMedCrossRefGoogle Scholar
- 27.DeMatteo RP, Owzar K, Antonescu CR et al (2008) Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US Intergroup phase II trial ACOSOG Z9000. ASCO 2008 Gastrointestinal Cancers Symposium (Abstract 8)Google Scholar
- 28.European Medicines Agency (2010) Glivec. EMA website. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000406/human_med_000808.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed 6 Feb 2013
- 30.Kang B Sr, Lee J, Ryu M et al (2009) A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol (Meeting Abstracts) 27:e21515Google Scholar
- 32.Casali PG, Le Cesne A, Velasco AP et al (2013) Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled Phase III trial. J Clin Oncol (Meeting Abstracts) 31:10500Google Scholar
- 33.ClinicalTrials.gov (2012) Five year adjuvant imatinib mesylate (Gleevec®) in gastrointestinal stromal tumor (GIST). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT00867113. Accessed 6 Feb 2013
- 35.Corless CL, Ballman KV, Antonescu C et al (2010) Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol (Meeting Abstracts) 28:10006Google Scholar
- 44.Joensuu H, Hohenberger P, Corless CL (2013) Gastrointestinal stromal tumour. Lancet [Epub ahead of print]Google Scholar
- 45.Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113PubMedCrossRefGoogle Scholar
- 47.Ray-Coquard IL, Bin Bui N, Adenis A et al (2010) Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol (Meeting Abstracts) 28:10032Google Scholar
- 48.Le Cesne A, Ray-Coquard IL, Bui Nguyen B et al (2011) Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. J Clin Oncol 29:10015Google Scholar
- 49.Domont J, Blay J, Ray-Coquard IL et al (2011) Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: result of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol 29:10054Google Scholar
- 50.Reichardt P, Hartmann J, Sundby Hall K et al (2011) Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment: the first analysis in the SSGXVIII/AIO trial patient population. Eur J Cancer 45:31LBAGoogle Scholar
- 51.Le Cesne A, Ray-Coquard I, Bin Bui N et al (2010) Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol (Meeting Abstracts) 28:10033Google Scholar